Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharmacogenomics. 2012 Dec;13(16):1937-50. doi: 10.2217/pgs.12.171.

Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients.

Author information

1
Department of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico, Room 420, PO Box 365067, San Juan, PR 00936-5067, USA.

Abstract

AIM:

This study was aimed at developing a pharmacogenetic-driven warfarin-dosing algorithm in 163 admixed Puerto Rican patients on stable warfarin therapy.

PATIENTS & METHODS:

A multiple linear-regression analysis was performed using log-transformed effective warfarin dose as the dependent variable, and combining CYP2C9 and VKORC1 genotyping with other relevant nongenetic clinical and demographic factors as independent predictors.

RESULTS:

The model explained more than two-thirds of the observed variance in the warfarin dose among Puerto Ricans, and also produced significantly better 'ideal dose' estimates than two pharmacogenetic models and clinical algorithms published previously, with the greatest benefit seen in patients ultimately requiring <7 mg/day. We also assessed the clinical validity of the model using an independent validation cohort of 55 Puerto Rican patients from Hartford, CT, USA (R(2) = 51%).

CONCLUSION:

Our findings provide the basis for planning prospective pharmacogenetic studies to demonstrate the clinical utility of genotyping warfarin-treated Puerto Rican patients.

PMID:
23215886
PMCID:
PMC3538136
DOI:
10.2217/pgs.12.171
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Support Center